RA
OVID icon

Royce & Associates’s Ovid Therapeutics OVID Stock Holding History

Royce & Associates’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,811
Closed -$37K – 975
2022
Q1 		$37K Buy
+11,811
New +$37.2K ﹤0.01% 957

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Royce & Associates's OVID Position: Q2 2022 in Review

Royce & Associates sold out of Ovid Therapeutics (OVID) in Q2 2022, closing a stake of 11,811 shares — an estimated $37K sold.

Royce & Associates first reported a position in OVID in Q1 2022 and held it in 1 quarter. The position peaked at $37K in Q1 2022. 55 funds tracked by Wall St. Rank hold OVID as of Q2 2022.

  • Royce & Associates reported no remaining Ovid Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Royce & Associates sold 11,811 Ovid Therapeutics shares in Q2 2022, an estimated $37K.
  • Royce & Associates first reported a position in Ovid Therapeutics in Q1 2022 and held it in 1 quarter.
  • Royce & Associates's Ovid Therapeutics position peaked at $37K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2022.

Based on Royce & Associates's 13F filing for Q2 2022, filed 4 Aug 2022.